Benzodiazepine analogues L365,260 and L364,718 as gastrin and pancreatic CCK receptor antagonists.
We examined the ability of the recently described 3-(benzoylamino)benzodiazepine analogue L365,260 and the 3-(acylamino)benzodiazepine analogue L364,718 to distinguish gastrin from pancreatic cholecystokinin (CCK) receptors. Neither L365,260 nor L364,718 when present alone (1 microM) caused stimulation of amylase release from guinea pig pancreatic acini or caused contraction of smooth muscle cells from guinea pig stomach. Each analogue inhibited CCK-stimulated amylase release, gastrin-17-I-stimulated smooth muscle contraction, binding of 125I-Bolton-Hunter-cholecystokinin octapeptide (125I-BH-CCK-8) to pancreatic CCK receptors, and binding of 125I-gastrin-17-I to gastrin receptors on pancreatic acini. L365,260, (Ki, 7.3 +/- 0.8 nM) was 50-70 times more potent than L364,718 at inhibiting binding of 125I-gastrin to pancreatic acini or gastrin-stimulated smooth muscle contraction. In contrast, L364,718 (Ki, 4 +/- 1 nM) was 145-200 times more potent than L365,260 at inhibiting binding of 125I-BH-CCK-8 to pancreatic acini or CCK-stimulated amylase release. Neither L364,718 nor L365,260 distinguished between high- and low-affinity CCK binding sites. L365,260 and L364,718 did not inhibit binding of radiolabeled vasoactive intestinal peptide, secretin, bombesin, substance P, or N-methylscopolamine to pancreatic acini. These results demonstrate that, in contrast to other gastrin-CCK receptor antagonists described, L365,260 is a selective gastrin receptor antagonist having an 80-fold higher affinity for gastrin than pancreatic CCK receptor, whereas L364,718 has a 125-fold higher affinity for pancreatic CCK receptors. Because of the selectivity of these two antagonists the involvement of CCK and gastrin in various physiological processes can be differentiated even when both receptors occur on the same cell.
Huang
S C
SC
Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland 20892.
Zhang
L
L
Chiang
H C
HC
Wank
S A
SA
Maton
P N
PN
Gardner
J D
JD
Jensen
R T
RT
D000681:Amylases / Q000378:metabolism; D000818:Animals; D001569:Benzodiazepines / Q000494:pharmacology*; D001570:Benzodiazepinones / Q000494:pharmacology*; D001667:Binding, Competitive; D002766:Cholecystokinin / Q000037:antagonists & inhibitors*; D020109:Devazepide; D005755:Gastrins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006168:Guinea Pigs; D007202:Indicators and Reagents; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000502:physiology; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism; D010671:Phenylurea Compounds; D011949:Receptors, Cholecystokinin / Q000502:physiology*; D012844:Sincalide / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D013270:Stomach / Q000502:physiology; D013388:Succinimides / Q000378:metabolism
D001570:Benzodiazepinones; C044758:Bolton Hunter-cholecystokinin octapeptide; D005755:Gastrins; D007202:Indicators and Reagents; D010671:Phenylurea Compounds; D011949:Receptors, Cholecystokinin; D013388:Succinimides; D001569:Benzodiazepines; C058121:L 365260; D002766:Cholecystokinin; C036227:gastrin I; D000681:Amylases; D020109:Devazepide; D012844:Sincalide